Company: NDRA
Filing Date: 2025-10-15
Form Type: 8-K
Source: 0001654954-25-011797
Chunk: 5

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-15
Form: 8-K
Item: Item 3.02
Chunk 5
---
Item 3.02 Unregistered Sales of Equity Securities.

In connection with the Offering, in addition to customary placement fees and reimbursement of certain expenses of the Placement Agent, on the Closing Date, the Company issued to the Placement Agent warrants (the “ Placement Agent Warrants”) to purchase up to an aggregate of 44,660 shares of Common Stock at an exercise price of $9.47 per share. The Placement Agent Warrants are exercisable for cash, in whole or in part, at any time and from time to time, for a period of three (3) years from the date of issuance and may also be exercised on a cashless basis at any time beginning six (6) months after their initial issuance if, at the time of exercise, there is no effective registration statement registering, or the prospectus contained therein is not available for, the resale of the underlying shares of Common Stock by the holder thereof.

The foregoing description of the Placement Agent Warrants does not purport to be complete and is qualified in its entirety by reference to the full text of the Form of Placement Agent Warrant, which is filed as Exhibit 4.3 hereto.

The Placement Agent Warrants were offered and sold in reliance upon the exemption from the registration requirements of the Securities Act, pursuant to Section 4(a)(2) thereof and/or Rule 506 of Regulation D promulgated thereunder, and applicable state securities laws.

The information contained above in Item 1.01 relating to the issuance of the Common Stock, the Shares, the Common Warrants, the Prefunded Warrants, and the Advisory Warrants is hereby incorporated by reference into this Item 3.02.

The issuances of the Shares, the Common Warrants, the Prefunded Warrants, the Placement Agent Warrants and the Advisory Warrants were not registered under the Securities Act and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws. Neither this Current Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy shares of Common Stock or other securities of the Company.

Item 5.08Shareholder Director Nominations.